REFERENCES
- Wicramasinghe S N. Congenital dyserythropoietic anemia, type 1: clinical features hematological morphology and new biochemical data. Blood Rev. 1998; 12: 178–200, [CSA]
- Shalev H, Tamary H, Shaft D, et al. Neonatal manifestations of congenital dyserythropoietic anemia type I. J Pediatr. 1997; 131: 95–97, [PUBMED], [INFOTRIEVE]
- Shalev H, Kapleushnik Y, Haeskelzon L, et al. Clinical and laboratory manifestations of congenital dyserythropoietic anemia type I in young adults. Eur J Haematol. 2002; 68: 170–174, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Alter B P, Young N S. The bone marrow failure syndromes. Nathan and Oski's Hematology of Infancy and Childhood., D G Nathan, S H Orkin. WB Saunders, Philadelphia 1998; 237–336
- Roda L, Pasche J, Fournier A, et al. Congenital dyserythropoietic anemia, type 1, in a Polynesian patient: response to interferon α2b. J Pediatr Hematol Oncol. 2002; 24: 503–506, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Parez N, Dommergues M, Zupan V, et al. Severe congenital dyserythropoietic anemia type I: prenatal management, transfusion support and alpha-interferon therapy. Br J Haematol. 2000; 110: 420–423, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shamseddine A, Taher A, Jaafar H, et al. Interferon alpha is an effective therapy for congenital dyserythropoietic anemia type I. Eur J Haematol. 2000; 65: 207–209, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wickramasinghe S N. Response of CDA type I to alpha-interferon. Eur J Haematol. 1997; 58: 121–123, [PUBMED], [INFOTRIEVE]
- Dgany O, Avidan N, Deaunay J, et al. Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet. 2002; 71: 1467–1474, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tamary H, Shalev V, Pinsk V, et al. No response to recombinant human erythropoietin in patients with congenital dyserythropoietic anemia type I. Pediatr Hematol Oncol. 1999; 16: 165–168, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wickramasinghe S N, Hasan R, Smythe J. Reduced interferon-alpha production by Epstein–Barr virus transformed B-lymphoblastoid cell lines and lectin-stimulated lymphocytes in congenital dyserythropoietic anemia type I. Br J Haematol. 1997; 98: 295–298, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Menike D, Wicramasinghe S N. Effects of four species of interferon-alpha on cultured erythroid progenitors from congenital dyserythropoietic anemia type I. Br J Haematol. 1998; 103: 825–423, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fattovich G, Guistina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol. 1996; 24: 38–47, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Csongor K. Interferons in pediatric oncology: end of the beginning or beginning of the end?. Med Pediatr Oncol. 1998; 30: 364–366, [CROSSREF]